Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
European Journal of Haematology
|
March 25, 2010
Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms
Anja Klostergaard, Rudi Steffensen, Jens K Møller, et al.
The Lancet. Haematology
|
February 5, 2025
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Frida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.
Ugeskrift for Laeger
|
May 4, 2018
[Neurogenic autonomic dysfunction in adults]
Astrid Juhl Terkelsen, John Hansen, Anja Klostergaard, et al.
Ugeskrift for Laeger
|
April 7, 2018
[Neurogenic autonomic dysfunction in primary amyliodosis]
Astrid Juhl Terkelsen, John Hansen, Anja Klostergaard, et al.
European Journal of Haematology
|
November 22, 2022
Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation
Lise Dueholm Bertelsen, Lars Børty Nielsen, Heidi Søgaard Christensen, et al.
Plos One
|
December 8, 2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
Rasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
September 25, 2019
Strategies to improve patient-reported outcome completion rates in longitudinal studies
Lene Kongsgaard Nielsen, Madeleine King, Sören Möller, et al.
Hemasphere
|
September 4, 2023
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Kazimierz Groen, Fredrik H Schjesvold, Bronno van der Holt, et al.
Haematologica
|
December 1, 2020
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Sonja Zweegman, Claudia A M Stege, Einar Haukas, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
European Journal of Haematology
|
March 25, 2010
Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms
Anja Klostergaard, Rudi Steffensen, Jens K Møller, et al.
The Lancet. Haematology
|
February 5, 2025
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Frida Bugge Askeland, Einar Haukås, Tobias S Slørdahl, et al.
Ugeskrift for Laeger
|
May 4, 2018
[Neurogenic autonomic dysfunction in adults]
Astrid Juhl Terkelsen, John Hansen, Anja Klostergaard, et al.
Ugeskrift for Laeger
|
April 7, 2018
[Neurogenic autonomic dysfunction in primary amyliodosis]
Astrid Juhl Terkelsen, John Hansen, Anja Klostergaard, et al.
European Journal of Haematology
|
November 22, 2022
Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation
Lise Dueholm Bertelsen, Lars Børty Nielsen, Heidi Søgaard Christensen, et al.
Plos One
|
December 8, 2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
Rasmus Sørrig, Tobias W Klausen, Morten Salomo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
September 25, 2019
Strategies to improve patient-reported outcome completion rates in longitudinal studies
Lene Kongsgaard Nielsen, Madeleine King, Sören Möller, et al.
Hemasphere
|
September 4, 2023
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Kazimierz Groen, Fredrik H Schjesvold, Bronno van der Holt, et al.
Haematologica
|
December 1, 2020
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Sonja Zweegman, Claudia A M Stege, Einar Haukas, et al.
Page
of 1